Loading clinical trials...
Loading clinical trials...
This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 month...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Advanz Pharma
NCT07430956 · Atrial Fibrillation (AF)
NCT07527299 · Atrial Fibrillation
NCT04695106 · Atrial Fibrillation, Antithrombotic Therapy, and more
NCT07441382 · Atrial Fibrillation (AF), Stroke, and more
NCT06784466 · Atrial Fibrillation (AF), Persistant Atrial Fibrillation, and more
The Heart Center, P.C.
Huntsville, Alabama
Cardiovascular Consultants Medical Group, Inc.
Walnut Creek, California
Penn State Heart & Vascular Institute
Hershey, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions